252 related articles for article (PubMed ID: 17453167)
1. [Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery].
Abbrederis K; Kremer M; Schuhmacher C
Chirurg; 2008 Apr; 79(4):351-5. PubMed ID: 17453167
[TBL] [Abstract][Full Text] [Related]
2. [Bevacizumab (Avastin) related surgical complications: comment to Abbrederis K et al. (2007)].
Lordick F; Siewert JR
Chirurg; 2008 Apr; 79(4):356-60. PubMed ID: 17453166
[No Abstract] [Full Text] [Related]
3. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
August DA; Serrano D; Poplin E
J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
[TBL] [Abstract][Full Text] [Related]
4. [Surgical management of bevacizumab-associated peritonitis due to perforation].
Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
[TBL] [Abstract][Full Text] [Related]
6. Extensive colonic ischemia following treatment with bevacizumab, fluouracil and CPT-11 in a young patient with advanced adenocarcinoma of the rectum.
Paran H; Edelstein E; Klein B; Gutman M
Isr Med Assoc J; 2007 Jun; 9(6):488-9. PubMed ID: 17642404
[No Abstract] [Full Text] [Related]
7. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
Heinzerling JH; Huerta S
Curr Surg; 2006; 63(5):334-7. PubMed ID: 16971205
[TBL] [Abstract][Full Text] [Related]
8. Early small bowel perforation due to aflibercept.
Moussallem T; Lim C; Osseis M; Esposito F; Lahat E; Fuentes L; Salloum C; Azoulay D
Drug Discov Ther; 2017 Nov; 11(5):291-292. PubMed ID: 29021501
[TBL] [Abstract][Full Text] [Related]
9. [A case of drug-induced lung injury associated with chemotherapy (FOLFOX6, FOLFIRI, Bevacizumab) for an advanced colon cancer].
Komaki C; Hanatate F; Kobayashi K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):113-6. PubMed ID: 21368470
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
[TBL] [Abstract][Full Text] [Related]
11. Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
Garant A; Des Groseilliers S; Martin L; Ferland É; Vuong T
Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):497-8. PubMed ID: 21576010
[No Abstract] [Full Text] [Related]
12. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
[TBL] [Abstract][Full Text] [Related]
13. When a good call leads to a bad connection: colovesical fistula in colorectal cancer treated with bevacizumab.
Chen J; Smalligan RD; Nadesan S
Hosp Pract (1995); 2016 Aug; 44(3):120-2. PubMed ID: 27309405
[TBL] [Abstract][Full Text] [Related]
14. [A case of severe bevacizumab-induced ischemic pancolitis, treated with conservative management].
Lee HN; Lee MA; Kim SW; Lim Y; Lee H; Lee HM; Won HS; Chun SH
Korean J Gastroenterol; 2011 Jul; 58(1):42-6. PubMed ID: 21778803
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.
Comella P; Massidda B; Natale D; Putzu C; Sandomenico C; Filippelli G; Palmeri S; Condemi G; Vessia G; Barberis G; Ionta MT; Tafuto S; Barbato E
Clin Colorectal Cancer; 2011 Mar; 10(1):42-7. PubMed ID: 21609935
[TBL] [Abstract][Full Text] [Related]
16. Managing patients treated with bevacizumab combination therapy.
Gordon MS; Cunningham D
Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
[TBL] [Abstract][Full Text] [Related]
17. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
Budai B; Nagy T; Láng I; Hitre E
Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
[TBL] [Abstract][Full Text] [Related]
18. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
[TBL] [Abstract][Full Text] [Related]
19. Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin.
Luo W; Liao WJ; Ma L; Huang YT; Shi M; Wen Q; Wang XN
Cancer Immunol Immunother; 2010 Feb; 59(2):247-56. PubMed ID: 19652968
[TBL] [Abstract][Full Text] [Related]
20. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
